Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Desmoteplase: Additional Phase III data

Paion said additional data from the previously reported Phase III DIAS-2 trial showed that a "high percentage of patients"

Read the full 190 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE